Does anyone know how their organisations (particularly health authorities
and PCTs) have managed the implementation of the NICE guidance on the
management of dementia -
Guidance on the use of Donepezil, Rivastigmine and Galantamine for the
Treatment of Alzheimer's Disease
For example what problems they are facing.
One of the Clinical Governance leads in one of our PCTs is looking into the
issue.
Thanks in advance.
Liz Farrell
Salford & Trafford HA
0161-787-0091
|